InCVAX is under clinical development by Immunophotonics and currently in Phase II for Hepatocellular Carcinoma. According to GlobalData, Phase II drugs for Hepatocellular Carcinoma have a 33% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how InCVAX’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
InCVAX overview
inCVAX is under development for the treatment of solid tumors including melanoma, soft tissue sarcoma, metastatic colorectal cancer (CRC), non-small cell lung cancer (NSCLC), hepatocellular carcinoma, colorectal cancer, non-small cell lung cancer, pancreatic cancer and coronavirus disease 2019 (COVID-19) as vaccine adjuvant. It is a laser-guided cancer vaccine therapy that utilizes the combination of a laser treatment, followed by injection at the treated tumor site with an immunological stimulant (Protectin). The therapeutic candidate is administered by intratumor route. It was under development for the treatment of stage III and IV metastatic breast cancer.
Immunophotonics overview
Immunophotonics is developing novel treatments for solid-tumor cancers. The company is headquartered in Saint Louis, Missouri, the US.
For a complete picture of InCVAX’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
